This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Strengthening focus in Alzheimer's disease and neuroscience pipeline
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Subscribe To Our Newsletter & Stay Updated
